New Approaches to Improved Vaccine Manufacturing in Embryonated Eggs - Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production. - BioPharm

ADVERTISEMENT

New Approaches to Improved Vaccine Manufacturing in Embryonated Eggs
Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.


BioPharm International Supplements


Conclusions

Recombinant vector technology offers a powerful way of extending long-standing experience with egg-based manufacturing to the fight against pandemic and neglected diseases. AdCEV vectors for use in eggs are being developed along with facilities that can be reconfigured to produce a sustainable mix of high value biologics and low cost vaccines in any economic context.

The recombinant adenovirus/egg technologies create a new category of production platform with unique economic, technical, and safety characteristics. The power to engineer the molecular processes of antigen production result in increases in yield, fidelity of product, and expansion of options for downstream processing. Changes in these parameters have far-reaching effects at the manufacturing process level including higher and more predictable yields from fewer eggs. This will potentially effect quality control issues that have traditionally dogged the egg-based vaccine industry.

A global system that can identify a pathogen, qualify targets in its lifecycle, then rapidly design and manufacture specific interventions to neutralize it is one of the most exciting promises of the post-genomic era. Ironically, such a system has existed for influenza for many decades, successfully operating on an annual cycle. Although it is ultimately desirable to move away from manufacturing in embryonated eggs, much can still be learned from this system. By offering significant improvements in biosafety and disruptive economics of scale, AdCEV/egg based systems could empower a sustainable, distributed manufacturing model more accessible to low and middle income countries and more resistant to biosecurity threats.

Eluemuno R. Blyden, PhD, is the founder and CEO of AfriVax, Inc., Seattle, WA,
Peter K. Watler, PhD, is a principal consultant and chief technology officer at Hyde Engineering + Consulting, Inc., South San Francisco, CA.

References

1. Matthews JT.Egg-Based Production of Influenza Vaccine: 30 Years of Commercial Experience. The Bridge. 2006;36(3): 17–24.

2. Hayden FG, Howard WA, Palkonyay L, Kieny MP. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12–13 February 2009. Vaccine. 2009 Jun 24;27(31):4079–89.

3. Fedson DS.New technologies for meeting the global demand for pandemic influenza vaccines. Biologicals. 2008 Nov;36(6):346–9.

4. Kieny MP, Costa A, Hombach J, Carrasco P, Pervikov Y, Salisbury D, et al. A global pandemic influenza vaccine action plan. Vaccine. 2006;24:6367–70.

5. Grabko VI, Blyden ER. Recombinant eggs and gene cloning and expression vectors based on avian adenoviruses. 2001. PCT Publication: WO0119968.

6. Corral T, Ver LS, Mottet G, Cano O, Garc쟭Barreno B, Calder LJ, et al. High level expression of soluble glycoproteins in the allantoic fluid of embryonated chicken eggs using a Sendai virus minigenome system. BMC Biotechnol. 2007;7:17.

7. Oliver Wyman. Influenza Vaccine Strategies for Broad Global Access. Seattle, Wa: Program for Appropriate Technology in Health (PATH); 2007.

8. FDA Warning Letter. Merck & Company, Inc., April 28, 2008.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here